Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

中国宏观投资环境 - 2025年以来中国继续加大创新投入推动新兴领域投资扩产促进新质生产力形成 [1] - 2025年前三季度大规模设备更新政策成效显著设备购置投资增速始终保持10%以上成为拉动投资增长的关键力量 [7] - 外资企业持续加码投资中国深化全产业链布局对中国经济韧性与市场机遇投下信任票 [1] 汽车行业 - 中国汽车工业向智能化和电动化加速转型吸引海外零部件供应商加大创新投入 [3] - 法雷奥集团2025年第三季度在上海竣工投产新制造基地专注于智能辅助驾驶领域生产智能驾驶摄像头、域控制器、激光雷达等产品 [3] - 中国是世界上最大的汽车市场已成为汽车行业的潮流引领者在电动汽车、智能辅助驾驶、高级辅助驾驶和软件定义汽车等领域走在前列 [5] - 法雷奥集团目标成为中国在汽车行业转型期的首选合作伙伴 [5] 电梯设备行业 - 中国电扶梯保有量全球第一在用电梯超过1100万部其中服役超过15年的电扶梯超过90万台形成庞大更新改造市场 [9] - 奥的斯参与的中国住宅电梯更新项目覆盖34个城市深度融入当地民生工程建设 [9] - 全球人口老龄化、建筑适老化趋势不断加深在中国市场尤为显著 [11] - 中国是奥的斯全球最大的电梯生产基地和全球最大的电梯市场也有最大的数字化服务网络 [11] 医药行业 - 中国在医疗等领域推出扩大开放政策为跨国企业创造更有利的投资环境 [13] - 法国医药企业赛诺菲宣布总投资达10亿欧元约合67亿元人民币的北京生产基地正式启动这是其在华最大单笔投资 [13] - 赛诺菲计划在北京新建一座胰岛素生产基地强化本土药品供应链韧性以更好地服务中国患者 [15] - 中国已成为赛诺菲的关键战略市场2025年恰逢其布局本土化生产30周年 [15]

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1DTzield is also being reviewed under the accelerated approval program Paris, October 20, 2025. The US Food and Drug Administration (FDA) has accepted for exped ...

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1DTzield is also being reviewed under the accelerated approval program Paris, October 20, 2025. The US Food and Drug Administration (FDA) has accepted for exped ...

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met all primary efficacy endpoints and was pre ...

（文章来源：每日经济新闻） 每经AI快讯，10月20日，赛诺菲发布声明称，根据10月17日发表于《柳叶刀》的最新研究数据，诺菲 高剂量流感疫苗Efluelda（北美市场名为Fluzone High-Dose）与标准剂量流感疫苗相比，能显著降低65 岁及以上老年人住院风险。 ...

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p<0.001) in adults 65 years and overResults come from FLUNITY-HD, the largest influenza vaccine effectiveness study of individually randomized older adults, involving nearly half a million ...

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p<0.001) in adults 65 years and overResults come from FLUNITY-HD, the largest influenza vaccine effectiveness study of individually randomized older adults, involving nearly half a million ...

公司战略与投资 - 赛诺菲将中国视为关键战略市场 对经济长期前景有信心 [1] - 赛诺菲在北京启动胰岛素原料药生产基地项目 总投资额达10亿欧元 [3] - 该生产基地是国内首个由跨国企业设立的胰岛素原料药生产基地 [3] 项目规模与规划 - 生产基地总建筑面积近6万平方米 预计于2032年全面建成并投入生产 [3] - 该项目是"十四五"以来北京市医药工业领域体量最大的投资项目 [3] 行业生态 - 北京经济技术开发区已聚集各类生物医药企业超5000家 [1] - 开发区构建起从研发 生产 服务到销售的全产业链体系 [1]